{"nctId":"NCT05062759","briefTitle":"Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma","startDateStruct":{"date":"2021-08-23","type":"ACTUAL"},"conditions":["Moderate to Severe Asthma"],"count":70,"armGroups":[{"label":"Tezepelumab","type":"EXPERIMENTAL","interventionNames":["Drug: Tezepelumab"]},{"label":"Placebo to Tezepelumab","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tezepelumab","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented physician-diagnosed asthma for at least 12 months prior to Visit 1.\n* Morning pre-bronchodilator FEV1 (Forced expiratory volume) of \\> 50% predicted normal value at Visit 1 or Visit 2.\n* Body weight ≥ 40 kg.\n* For women of childbearing potential, a negative urine pregnancy test is required prior to administration of study intervention at Visit 3.\n* Must have 'not well-controlled' asthma.\n\nExclusion Criteria:\n\n* Clinically important pulmonary disease other than asthma.\n* Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment.\n* Life-threatening asthma\n* History of cancer.\n* Allergy to eggs, if egg based influenza vaccine will be administered.\n* History of anaphylaxis to any biologic therapy.\n* Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of \\< 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.\n* History of alcohol or drug abuse within 12 months prior to the date of informed consent.\n* Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures during the conduct of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Post-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs)","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.\n\nHAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.34","spread":"1.361"},{"groupId":"OG001","value":"4.75","spread":"1.455"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"0.955"},{"groupId":"OG001","value":"1.46","spread":"0.937"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":"1.054"},{"groupId":"OG001","value":"2.90","spread":"0.841"}]}]}]},{"type":"PRIMARY","title":"Post-vaccination Strain-specific Microneutralization (MN) Antibody GMFRs","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.56","spread":"2.581"},{"groupId":"OG001","value":"10.62","spread":"2.409"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.73","spread":"1.509"},{"groupId":"OG001","value":"5.90","spread":"3.180"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":"1.541"},{"groupId":"OG001","value":"3.56","spread":"2.206"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.08","spread":"2.279"},{"groupId":"OG001","value":"5.04","spread":"1.723"}]}]}]},{"type":"PRIMARY","title":"Post-vaccination Strain-specific Serum HAI Antibody Geometric Mean Titers (GMTs)","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.\n\nHAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"809.23","spread":"0.921"},{"groupId":"OG001","value":"596.76","spread":"1.076"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167.46","spread":"0.925"},{"groupId":"OG001","value":"161.56","spread":"0.688"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"194.68","spread":"1.089"},{"groupId":"OG001","value":"200.55","spread":"0.948"}]}]}]},{"type":"PRIMARY","title":"Post-vaccination Strain-specific Serum MN Antibody GMTs","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"382.55","spread":"1.469"},{"groupId":"OG001","value":"303.63","spread":"1.667"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"600.92","spread":"2.154"},{"groupId":"OG001","value":"457.33","spread":"2.336"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"355.44","spread":"1.076"},{"groupId":"OG001","value":"366.81","spread":"1.270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125.67","spread":"4.687"},{"groupId":"OG001","value":"124.35","spread":"3.515"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in HAI Antibody Titer","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.\n\nHAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":"63.82"},{"groupId":"OG001","value":"51.5","spread":"36.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"6.17"},{"groupId":"OG001","value":"15.2","spread":"6.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":"17.46"},{"groupId":"OG001","value":"39.4","spread":"25.11"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in MN Antibody Titer","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.\n\nVaccine immunogenicity analysis set consisted of all randomised patients who received the influenza vaccine plus at least 1 dose of tezepelumab or placebo, had pre and post vaccination HAI or MN antibody measurements, had no influenza infection prior to Visit 7 (Week 16), and had no protocol deviation, judged to have the potential to interfere with the generation or interpretation of an antibody response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":"67.24"},{"groupId":"OG001","value":"75.8","spread":"60.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":"44.82"},{"groupId":"OG001","value":"51.5","spread":"36.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":"36.07"},{"groupId":"OG001","value":"36.4","spread":"22.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":"38.94"},{"groupId":"OG001","value":"63.6","spread":"47.84"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Post-vaccination Strain-specific HAI Antibody Titer ≥ 40","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.\n\nHAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":"91.32"},{"groupId":"OG001","value":"100","spread":"91.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":"86.41"},{"groupId":"OG001","value":"100","spread":"91.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":"91.32"},{"groupId":"OG001","value":"97.0","spread":"86.41"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Post-vaccination Strain-specific MN Antibody Titer ≥ 40","description":"Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":"91.32"},{"groupId":"OG001","value":"93.9","spread":"82.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":"82.13"},{"groupId":"OG001","value":"97","spread":"86.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":"86.41"},{"groupId":"OG001","value":"100","spread":"91.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":"63.82"},{"groupId":"OG001","value":"81.8","spread":"67.24"}]}]}]},{"type":"SECONDARY","title":"Serum Tezepelumab Concentrations","description":"Tezepelumab serum concentrations were summarized using descriptive statistics at each visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.00","spread":"0.5421"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.76","spread":"3.6969"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.79","spread":"1.0705"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity","description":"Immunogenicity assessments were performed. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["COVID-19","Acute sinusitis","Ear infection","Viral upper respiratory tract infection","Arthralgia"]}}}